In addition to the indications mentioned above, ADT is also being used in some patients with early-stage prostate cancer and in those with biochemical recurrence (rising prostate-specific antigen [PSA] levels following initial remission after prostatectomy). This evidence concerns the gene KLK3 and prostate carcinoma.